KBY Biotech Indexv0.0.34
Search
← Pipeline|415-3897

415-3897

Phase 3
By Kyowa Kirin
Source: Trial-derived·Trials: 4
Modality
ADC
MOA
WRNi
Target
GLP-1R
Pathway
NF-κB
Ewing SarcomaMGFabry
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
Jun 2017
→ Aug 2029
Phase 3Current
NCT08430941
1,508 pts·Fabry
2020-01→2029-08·Terminated
NCT04204962
2,825 pts·Ewing Sarcoma
2022-12→2025-04·Completed
NCT07830833
2,200 pts·Fabry
2018-03→2029-02·Recruiting
+1 more trial
7,593 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (5)
2025-04-1611mo agoPh3 Readout· Ewing Sarcoma
2025-12-044mo agoEMA Filing· Fabry
2026-10-116mo awayPh3 Readout· Ewing Sarcoma
2029-02-172.9y awayPh3 Readout· Fabry
2029-08-093.4y awayPh3 Readout· Fabry
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Not yet…
P3
Recruit…
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2025-04-16 · 11mo ago
Ewing Sarcoma
EMA Filing
2025-12-04 · 4mo ago
Fabry
Ph3 Readout
2026-10-11 · 6mo away
Ewing Sarcoma
Ph3 Readout
2029-02-17 · 2.9y away
Fabry
Ph3 Readout
2029-08-09 · 3.4y away
Fabry
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT08430941Phase 3FabryTerminated1508NT-proBNP
NCT04204962Phase 3Ewing SarcomaCompleted2825Safety
NCT07830833Phase 3FabryRecruiting2200UPCR
NCT03098628Phase 3Ewing SarcomaNot yet recr...1060PFS
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-2191PfizerNDA/BLAGLP-1RSHP2i
RiboinavolisibJohnson & JohnsonPhase 2/3GLP-1RMALT1i
TirzepatideEli LillyApprovedGLP-1RGLP-1/GIP Dual Agonist
MRK-5413Merck & CoPhase 1GLP-1RVEGFi
ABB-1817AbbViePhase 3SHP2WRNi
VoxacilimabAstraZenecaPhase 1/2GLP-1RPI3Ki
AZN-5171AstraZenecaApprovedGLP-1RGLP-1/GIP
BMY-7975Bristol-Myers SquibbPhase 1MALT1WRNi
GSK-4334GSKPreclinicalCD47WRNi
MavuglumideBayerApprovedGLP-1RCDK2i